Table 1.

Number (%) of prostate cancer cases and their controls according to certain socioeconomic and clinical characteristics

CaseControl
(N = 9,384)(N = 46,749)
Age group
 40–55793 (8.5%)3,976 (8.5%)
 56–601,045 (11.1%)5,215 (11.2%)
 61–651,606 (17.1%)8,015 (17.1%)
 66–701,858 (19.8%)9,270 (19.8%)
 71–751,630 (17.4%)8,105 (17.3%)
 76–801,179 (12.6%)5,862 (12.5%)
 81+1,273 (13.6%)6,306 (13.5%)
Rural residence3,735 (39.8%)18,508 (39.6%)
Income quintile
 Q1 (lowest)1,459 (15.5%)8,147 (17.4%)
 Q21,860 (19.8%)9,433 (20.2%)
 Q31,889 (20.1%)9,776 (20.9%)
 Q41,989 (21.2%)9,605 (20.5%)
 Q5 (highest)2,009 (21.4%)8,664 (18.5%)
 Unknown178 (1.9%)1,124 (2.4%)
Ever use of statins
 Any statin2,299 (24.5%)11,794 (25.2%)
 Atorvastatin1,460 (15.6%)7,455 (15.9%)
 Cerivastatin132 (1.4%)692 (1.5%)
 Fluvastatin73 (0.8%)323 (0.7%)
 Lovastatin92 (1.0%)520 (1.1%)
 Pravastatin237 (2.5%)1,340 (2.9%)
 Rosuvastatin442 (4.7%)2,181 (4.7%)
 Simvastatin567 (6.0%)2,892 (6.2%)
Ever use of other prescription drugs
 Non-statin lipid-lowering drug452 (4.8%)2,500 (5.3%)
 Metformin693 (7.4%)4,237 (9.1%)
 Other oral hypoglycemic drug561 (6.0%)3,562 (7.6%)
 Insulin155 (1.7%)975 (2.1%)
 Aspirin1,306 (13.9%)7,070 (15.1%)
 Non-aspirin NSAID3,880 (41.3%)18,646 (39.9%)
Any chronic disease4,610 (49.1%)23,387 (50.0%)
 Chronic cardiovascular disease (excluding hypertension)2,793 (29.8%)14,511 (31.0%)
 Peripheral cardiovascular disease674 (7.2%)3,298 (7.1%)
 Diabetes1,560 (16.6%)8,904 (19.0%)
 Chronic renal failure258 (2.7%)1,110 (2.4%)
 Chronic respiratory disease (excluding asthma)1,220 (13.0%)6,433 (13.8%)
 Chronic liver disease53 (0.6%)304 (0.7%)
Number of physician visits in the 5-year period before the index date
 0–191,700 (18.1%)11,929 (25.5%)
 20–392,937 (31.3%)13,584 (29.1%)
 40–592,140 (22.8%)9,525 (20.4%)
 60+2,607 (27.8%)11,711 (25.1%)
Number of hospitalizations in the 5-year period before the index date
 04,266 (45.5%)23,323 (49.9%)
 12,193 (23.4%)9,731 (20.8%)
 21,206 (12.9%)5,544 (11.9%)
 3700 (7.5%)3,067 (6.6%)
 4+1,019 (10.9%)5,084 (10.9%)
Screening indicatora7,271 (77.5%)16,452 (35.2%)
  • aHyperplasia, inflammation, or disorder of the prostate in the year before the index date or a urologist visit 1–11 years before the index date.